United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 4 minute read Pharma Industry News How do Vutrisiran’s HELIOS-B results compare with historical standards in ATTR-CM treatment? Alnylam’s vutrisiran reduces cardiovascular mortality and urgent heart failure visits in ATTR-CM, reinforcing AMVUTTRA’s first-line potential. Read key data now. byPallavi MadhirajuMay 18, 2025